IQVIA Holdings Inc. (NYSE:IQV) Shares Bought by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 79,599 shares of the medical research company’s stock after acquiring an additional 1,206 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in IQVIA were worth $18,418,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of IQV. HighTower Advisors LLC lifted its position in IQVIA by 2.4% in the 1st quarter. HighTower Advisors LLC now owns 5,055 shares of the medical research company’s stock valued at $1,168,000 after purchasing an additional 118 shares during the last quarter. Prudential PLC bought a new stake in IQVIA in the 1st quarter valued at about $741,000. Baird Financial Group Inc. lifted its position in IQVIA by 2.3% in the 1st quarter. Baird Financial Group Inc. now owns 99,566 shares of the medical research company’s stock valued at $23,021,000 after purchasing an additional 2,201 shares during the last quarter. Parkside Financial Bank & Trust lifted its position in IQVIA by 59.0% in the 1st quarter. Parkside Financial Bank & Trust now owns 388 shares of the medical research company’s stock valued at $90,000 after purchasing an additional 144 shares during the last quarter. Finally, Covestor Ltd lifted its position in IQVIA by 82.2% in the 1st quarter. Covestor Ltd now owns 554 shares of the medical research company’s stock valued at $128,000 after purchasing an additional 250 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Performance

IQVIA stock opened at $227.17 on Friday. The firm’s 50 day simple moving average is $244.62 and its 200-day simple moving average is $221.41. The company has a market cap of $41.23 billion, a P/E ratio of 31.16, a price-to-earnings-growth ratio of 2.20 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.86 and a quick ratio of 0.86. IQVIA Holdings Inc. has a fifty-two week low of $167.42 and a fifty-two week high of $261.73.

IQVIA (NYSE:IQV) last released its earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, topping the consensus estimate of $2.82 by $0.02. The business had revenue of $3.87 billion for the quarter, compared to the consensus estimate of $3.80 billion. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The firm’s quarterly revenue was up 3.5% compared to the same quarter last year. During the same period last year, the firm posted $2.54 earnings per share. As a group, equities research analysts predict that IQVIA Holdings Inc. will post 10.11 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on IQV. Leerink Partnrs restated an “outperform” rating on shares of IQVIA in a research report on Monday, February 26th. UBS Group boosted their price target on shares of IQVIA from $240.00 to $300.00 and gave the stock a “buy” rating in a research report on Thursday, February 15th. StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Friday, February 16th. Guggenheim cut shares of IQVIA from a “buy” rating to a “neutral” rating in a research note on Thursday, February 15th. Finally, Evercore ISI lifted their price objective on shares of IQVIA from $255.00 to $265.00 and gave the stock a “market outperform” rating in a research note on Thursday, February 15th. Three investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and a consensus target price of $256.80.

Insider Buying and Selling

In related news, insider Kevin C. Knightly sold 8,607 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the completion of the sale, the insider now directly owns 5,251 shares in the company, valued at $1,313,642.67. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other IQVIA news, insider Eric Sherbet sold 1,000 shares of IQVIA stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $241.50, for a total value of $241,500.00. Following the completion of the sale, the insider now directly owns 20,836 shares in the company, valued at $5,031,894. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kevin C. Knightly sold 8,607 shares of IQVIA stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the completion of the sale, the insider now owns 5,251 shares of the company’s stock, valued at $1,313,642.67. The disclosure for this sale can be found here. Over the last three months, insiders sold 41,285 shares of company stock worth $10,331,003. 1.60% of the stock is owned by company insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.